Solentim wins New Product Award at SLAS 2021
Bournemouth, UK, 29th January 2021 / Sciad Newswire / Solentim is delighted to have won a New Product Award from the Society for Laboratory Automation and Screening (SLAS), annouced this week at SLAS Digital 2021. Solentim achieved this award with the launch of its new ICON™ and STUDIUS™ technologies.
ICON is the world’s first benchtop system for characterizing high productivity clones in cell line development. Using rapid assays for the three critical quality attributes of titer, cell number and cell viability, ICON assesses cell productivity to enable characterization of leading candidates. STUDIUS is Solentim’s proprietary software platform delivering unparalleled data on the journey of each individual cell, controlling, managing and reporting on cell line development processes to enable smarter decision making earlier.
Together, these two new technologies mark the launch of Solentim’s new, all-encompassing solution for cell line development. In combination with the company’s existing VIPS™ and Cell Metric® instruments, ICON and STUDIUS complete the creation of a secure cell line development ecosystem.
Mark Truesdale, CEO, Solentim, commented: “We’re delighted with the award and SLAS’s recognition of the value of ICON and STUDIUS. The launch of these products completes a ten-year journey to redesign the cell line development workflow and the start of a new generation of laboratory practices. With our instruments and technologies, scientists can enjoy accelerated, assurance rich workflows as they design the medicines of tomorrow. Thanks to SLAS for arranging this year’s event digitally.”
Please do get in touch for further information about our complete ecosystem solution for cell line development.
For further information, contact:
Duncan Borthwick, Global Marketing Manager
T: +44 (0)1202 798510
Sciad Communications Ltd
Emma Pickup/Richard Anderson
T: +44 (0)20 3405 7892
Notes to Editors
Solentim is the trusted global leader in cell therapy workflows enabling the creation, isolation and characterization of high value cells. In the pursuit of new biological medicines, our data rich portfolio of industry accepted technologies drives accelerated development of Master Cell Banks. For our customers, which include most of the world’s leading pharmaceutical and biotherapeutics companies, we are the partner of choice for facilitating the highest level of assurance in cell line development for therapeutic protein and viral vector production.
Our portfolio of proven and innovative instruments (including VIPS™, Cell Metric®, Cell Metric® CLD and ICON™) are designed for single cell cloning and assurance of monoclonality. Combined with enabling reagents (including InstiGRO™ and Leap-In Transposase®) from our partners, and our unparalleled domain expertise, we transform the speed and efficiency of clonally-derived Master Cell Bank development. Our customers trust in our technology to ensure they are confidently prepared for regulatory review.